drugset / Trial / NCT04991207

Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Bosentan

NCT04991207

Phase 1 Completed 44 enrolled Bial - Portela C S.A.
RandomizedSequentialOpen-labelTreatment

Summary

the purpose of this study is: * To assess the effect of BIA 5 1058 400 mg on the PK of bosentan. * To assess the effect of bosentan on the PK of BIA 5 1058

Timeline

Start
2018-02-06
Primary completion
2018-05-14
Completion
2018-05-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Bosentan Other / unclassified 125 mg Oral
Subject zamicastat Small molecule 400 mg Oral